JP2013522376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522376A5 JP2013522376A5 JP2013501494A JP2013501494A JP2013522376A5 JP 2013522376 A5 JP2013522376 A5 JP 2013522376A5 JP 2013501494 A JP2013501494 A JP 2013501494A JP 2013501494 A JP2013501494 A JP 2013501494A JP 2013522376 A5 JP2013522376 A5 JP 2013522376A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- composition
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 106
- 150000003839 salts Chemical class 0.000 claims description 90
- 125000000217 alkyl group Chemical group 0.000 claims description 75
- 125000003118 aryl group Chemical group 0.000 claims description 68
- 239000000203 mixture Substances 0.000 claims description 66
- 229910052739 hydrogen Inorganic materials 0.000 claims description 64
- 239000001257 hydrogen Substances 0.000 claims description 64
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 62
- 125000001072 heteroaryl group Chemical group 0.000 claims description 56
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 50
- 125000003342 alkenyl group Chemical group 0.000 claims description 44
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 42
- 229910052736 halogen Inorganic materials 0.000 claims description 42
- 150000002367 halogens Chemical class 0.000 claims description 42
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 40
- 239000003795 chemical substances by application Substances 0.000 claims description 36
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 32
- 125000001424 substituent group Chemical group 0.000 claims description 31
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 230000002207 retinal effect Effects 0.000 claims description 18
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 14
- 230000037396 body weight Effects 0.000 claims description 12
- 125000001165 hydrophobic group Chemical group 0.000 claims description 12
- 230000001796 anti-degenerative effect Effects 0.000 claims description 10
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 8
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- -1 cyano, nitro, amino Chemical group 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 238000011287 therapeutic dose Methods 0.000 claims description 6
- 238000011200 topical administration Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 108010030583 (melle-4)cyclosporin Proteins 0.000 claims description 4
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims description 4
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 4
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 4
- LAMQVIQMVKWXOC-UHFFFAOYSA-N 4-methyl-n-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2C=NC=CC=2)SC=1C(=O)NC1=CC=CC=C1C(N=C1SC=2)=CN1C=2CN1CCOCC1 LAMQVIQMVKWXOC-UHFFFAOYSA-N 0.000 claims description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 208000014644 Brain disease Diseases 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 4
- 108010036949 Cyclosporine Proteins 0.000 claims description 4
- 208000032274 Encephalopathy Diseases 0.000 claims description 4
- 108010008165 Etanercept Proteins 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical class C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 4
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 4
- 201000007737 Retinal degeneration Diseases 0.000 claims description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical class C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 230000001064 anti-interferon Effects 0.000 claims description 4
- 230000006907 apoptotic process Effects 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 229940120638 avastin Drugs 0.000 claims description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 150000001721 carbon Chemical group 0.000 claims description 4
- 229960001265 ciclosporin Drugs 0.000 claims description 4
- 229930182912 cyclosporin Natural products 0.000 claims description 4
- 229960000403 etanercept Drugs 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 239000006194 liquid suspension Substances 0.000 claims description 4
- 229940076783 lucentis Drugs 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 230000007102 metabolic function Effects 0.000 claims description 4
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims description 4
- 229960004023 minocycline Drugs 0.000 claims description 4
- 230000002438 mitochondrial effect Effects 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- RPJPZDVUUKWPGT-FOIHOXPVSA-N nim811 Chemical compound CC[C@H](C)[C@@H]1N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC1=O RPJPZDVUUKWPGT-FOIHOXPVSA-N 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 230000036542 oxidative stress Effects 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000005412 pyrazyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 229960001285 quercetin Drugs 0.000 claims description 4
- 235000005875 quercetin Nutrition 0.000 claims description 4
- 229940016667 resveratrol Drugs 0.000 claims description 4
- 235000021283 resveratrol Nutrition 0.000 claims description 4
- 230000004258 retinal degeneration Effects 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 150000003852 triazoles Chemical class 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- 125000004385 trihaloalkyl group Chemical group 0.000 claims description 4
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 229940097496 nasal spray Drugs 0.000 claims description 3
- 239000007922 nasal spray Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 2
- HIYWOHBEPVGIQN-UHFFFAOYSA-N 1h-benzo[g]indole Chemical compound C1=CC=CC2=C(NC=C3)C3=CC=C21 HIYWOHBEPVGIQN-UHFFFAOYSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000035172 MERRF Diseases 0.000 claims description 2
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 2
- 206010056677 Nerve degeneration Diseases 0.000 claims description 2
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 claims description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical class C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- 101100240886 Rattus norvegicus Nptx2 gene Proteins 0.000 claims description 2
- 208000027073 Stargardt disease Diseases 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 238000000889 atomisation Methods 0.000 claims description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 229940012356 eye drops Drugs 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 230000010370 hearing loss Effects 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 2
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical class C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical class C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 208000006443 lactic acidosis Diseases 0.000 claims description 2
- 230000006676 mitochondrial damage Effects 0.000 claims description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 210000001328 optic nerve Anatomy 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000008085 renal dysfunction Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 229930192474 thiophene Chemical class 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 239000013022 formulation composition Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 230000002151 myoclonic effect Effects 0.000 claims 1
- 239000007923 nasal drop Substances 0.000 claims 1
- 229940100662 nasal drops Drugs 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 150000003557 thiazoles Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 39
- 0 CC*1NC(c2cnccc2)=NC1C1C=CC=CC1 Chemical compound CC*1NC(c2cnccc2)=NC1C1C=CC=CC1 0.000 description 4
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- RTGYIWNSBMCIAT-UHFFFAOYSA-N C(C(C1)=C(c2ccccc2)N=C1c1cnccc1)OCNc1ccccc1 Chemical compound C(C(C1)=C(c2ccccc2)N=C1c1cnccc1)OCNc1ccccc1 RTGYIWNSBMCIAT-UHFFFAOYSA-N 0.000 description 1
- XMWINMVFKPHMJB-UHFFFAOYSA-N CC1=CCCC=C1 Chemical compound CC1=CCCC=C1 XMWINMVFKPHMJB-UHFFFAOYSA-N 0.000 description 1
- HMXPNSGDSXNSLY-GZTJUZNOSA-N CCC(C=C)/C=C(\C=C)/C1=C(CCC=C)NNN1CC1=CN=CC2C1C2 Chemical compound CCC(C=C)/C=C(\C=C)/C1=C(CCC=C)NNN1CC1=CN=CC2C1C2 HMXPNSGDSXNSLY-GZTJUZNOSA-N 0.000 description 1
- HHWOCFUWBBPTGX-UHFFFAOYSA-N CCCCN(c1ncc[nH]1)NC(Cc1ccccc1)=N Chemical compound CCCCN(c1ncc[nH]1)NC(Cc1ccccc1)=N HHWOCFUWBBPTGX-UHFFFAOYSA-N 0.000 description 1
- XLYDILVNSZWGIW-UHFFFAOYSA-N CCCCN(c1ncc[nH]1)NC(c1cnccc1)=O Chemical compound CCCCN(c1ncc[nH]1)NC(c1cnccc1)=O XLYDILVNSZWGIW-UHFFFAOYSA-N 0.000 description 1
- YHUBKBIPCUAGIP-OIBXWCBGSA-N CCCC[C@@H](c1ccccc11)N(CCC[C@@H]2CCc3cnccc3)[C@@]12O Chemical compound CCCC[C@@H](c1ccccc11)N(CCC[C@@H]2CCc3cnccc3)[C@@]12O YHUBKBIPCUAGIP-OIBXWCBGSA-N 0.000 description 1
- RHSZMZJITHJKNU-NYVOZVTQSA-N CCCC[C@@H](c1ccccc11)N(CC[C@@H]2CCc3cnccc3)[C@@]12O Chemical compound CCCC[C@@H](c1ccccc11)N(CC[C@@H]2CCc3cnccc3)[C@@]12O RHSZMZJITHJKNU-NYVOZVTQSA-N 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- SLGWHMWDUJTHHY-UHFFFAOYSA-N N=C1N(c2ccccc2)c(cccc2)c2C2=C1CC(c1cnccc1)=N2 Chemical compound N=C1N(c2ccccc2)c(cccc2)c2C2=C1CC(c1cnccc1)=N2 SLGWHMWDUJTHHY-UHFFFAOYSA-N 0.000 description 1
- UMEZSLWYVVQFTF-UHFFFAOYSA-N O=C(Cc1ccccc1)NN(Cc1cnccc1)c1ncc[nH]1 Chemical compound O=C(Cc1ccccc1)NN(Cc1cnccc1)c1ncc[nH]1 UMEZSLWYVVQFTF-UHFFFAOYSA-N 0.000 description 1
- MKXMQVPQNAUXJZ-UHFFFAOYSA-N O=C(Cc1ccncc1)NN(Cc1ccccc1)c1ncc[nH]1 Chemical compound O=C(Cc1ccncc1)NN(Cc1ccccc1)c1ncc[nH]1 MKXMQVPQNAUXJZ-UHFFFAOYSA-N 0.000 description 1
- HENFPEGPZQODEC-UHFFFAOYSA-N O=C(c1cnccc1)NN(Cc1ccccc1)c1ncc[nH]1 Chemical compound O=C(c1cnccc1)NN(Cc1ccccc1)c1ncc[nH]1 HENFPEGPZQODEC-UHFFFAOYSA-N 0.000 description 1
- ZTCCFPQTSSNJCW-UHFFFAOYSA-N O=C(c1cnccc1)NNC1=CCCC1 Chemical compound O=C(c1cnccc1)NNC1=CCCC1 ZTCCFPQTSSNJCW-UHFFFAOYSA-N 0.000 description 1
- FWOLAQNIJKLJCP-UHFFFAOYSA-N OC(CC(c1ncccc1)=O)(c(cccc1)c1N1Cc2cccc(C(OC(C3)c4ncccc4)OC3(c(cccc3)c3N3Cc4ccccc4)C3=O)c2)C1=O Chemical compound OC(CC(c1ncccc1)=O)(c(cccc1)c1N1Cc2cccc(C(OC(C3)c4ncccc4)OC3(c(cccc3)c3N3Cc4ccccc4)C3=O)c2)C1=O FWOLAQNIJKLJCP-UHFFFAOYSA-N 0.000 description 1
- QSFYHGXOINLAEA-OYDLWJJNSA-N O[C@]1([C@@H](CCc2cnccc2)CC2)N2[C@@H](CC2=CC=CC2)c2ccccc12 Chemical compound O[C@]1([C@@H](CCc2cnccc2)CC2)N2[C@@H](CC2=CC=CC2)c2ccccc12 QSFYHGXOINLAEA-OYDLWJJNSA-N 0.000 description 1
- QBGGPLZEACGASW-TZYHBYERSA-N O[C@]1([C@@H](CCc2cnccc2)CC2)N2[C@@H](Cc2ccc[o]2)c2ccccc12 Chemical compound O[C@]1([C@@H](CCc2cnccc2)CC2)N2[C@@H](Cc2ccc[o]2)c2ccccc12 QBGGPLZEACGASW-TZYHBYERSA-N 0.000 description 1
- DXBSFZHOSDGFLC-TUSQITKMSA-N O[C@]1([C@@H](CCc2cnccc2)CC2)N2[C@@H](Cc2ccccc2)c2c1cccc2 Chemical compound O[C@]1([C@@H](CCc2cnccc2)CC2)N2[C@@H](Cc2ccccc2)c2c1cccc2 DXBSFZHOSDGFLC-TUSQITKMSA-N 0.000 description 1
- NFSJWDWGUGWEGB-XJABCFGWSA-N O[C@]1([C@@H](CCc2cnccc2)CC2)N2[C@@H](Cc2ncc[nH]2)c2c1cccc2 Chemical compound O[C@]1([C@@H](CCc2cnccc2)CC2)N2[C@@H](Cc2ncc[nH]2)c2c1cccc2 NFSJWDWGUGWEGB-XJABCFGWSA-N 0.000 description 1
- ODHANUGBVFWHPA-ZODMCCGTSA-N O[C@]1([C@@H](CCc2cnccc2)CCC2)N2[C@@H](CC2=CC=CC2)c2ccccc12 Chemical compound O[C@]1([C@@H](CCc2cnccc2)CCC2)N2[C@@H](CC2=CC=CC2)c2ccccc12 ODHANUGBVFWHPA-ZODMCCGTSA-N 0.000 description 1
- UWYOTTNSWZZLCG-RZFJZAQRSA-N O[C@]1([C@@H](CCc2cnccc2)CCC2)N2[C@@H](Cc2ccccc2)c2c1cccc2 Chemical compound O[C@]1([C@@H](CCc2cnccc2)CCC2)N2[C@@H](Cc2ccccc2)c2c1cccc2 UWYOTTNSWZZLCG-RZFJZAQRSA-N 0.000 description 1
- XQXXAXMETGZRSO-OYDLWJJNSA-N O[C@]1([C@@H](CCc2cnccc2)COC2)N2[C@@H](CC2=CC=CC2)c2ccccc12 Chemical compound O[C@]1([C@@H](CCc2cnccc2)COC2)N2[C@@H](CC2=CC=CC2)c2ccccc12 XQXXAXMETGZRSO-OYDLWJJNSA-N 0.000 description 1
- ZWCZEBLEOGHBTF-TZYHBYERSA-N O[C@]1([C@@H](CCc2cnccc2)COC2)N2[C@@H](Cc2ccc[o]2)c2ccccc12 Chemical compound O[C@]1([C@@H](CCc2cnccc2)COC2)N2[C@@H](Cc2ccc[o]2)c2ccccc12 ZWCZEBLEOGHBTF-TZYHBYERSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31718510P | 2010-03-24 | 2010-03-24 | |
| US61/317,185 | 2010-03-24 | ||
| PCT/US2011/029846 WO2011119869A1 (en) | 2010-03-24 | 2011-03-24 | Compositions and methods for the treatment of degenerative diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015189524A Division JP2015232051A (ja) | 2010-03-24 | 2015-09-28 | 変性疾患を治療するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013522376A JP2013522376A (ja) | 2013-06-13 |
| JP2013522376A5 true JP2013522376A5 (enExample) | 2014-05-08 |
Family
ID=43927957
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501494A Pending JP2013522376A (ja) | 2010-03-24 | 2011-03-24 | 変性疾患を治療するための組成物および方法 |
| JP2015189524A Pending JP2015232051A (ja) | 2010-03-24 | 2015-09-28 | 変性疾患を治療するための組成物および方法 |
| JP2016156126A Pending JP2016188257A (ja) | 2010-03-24 | 2016-08-09 | 変性疾患を治療するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015189524A Pending JP2015232051A (ja) | 2010-03-24 | 2015-09-28 | 変性疾患を治療するための組成物および方法 |
| JP2016156126A Pending JP2016188257A (ja) | 2010-03-24 | 2016-08-09 | 変性疾患を治療するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130137728A1 (enExample) |
| EP (1) | EP2550260A1 (enExample) |
| JP (3) | JP2013522376A (enExample) |
| AU (1) | AU2011232347B2 (enExample) |
| CA (1) | CA2794018C (enExample) |
| WO (1) | WO2011119869A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2861611T (pt) | 2012-05-25 | 2016-10-11 | Janssen Sciences Ireland Uc | Nucleósidos de espirooxetano de uracilo |
| WO2014059008A1 (en) | 2012-10-09 | 2014-04-17 | The Procter & Gamble Company | Method of identifying or evaluating beneficial actives and compositions containing the same |
| CN104703585A (zh) | 2012-10-09 | 2015-06-10 | 宝洁公司 | 鉴定协同化妆品组合的方法 |
| US9243022B2 (en) | 2012-12-21 | 2016-01-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9079853B2 (en) | 2013-02-07 | 2015-07-14 | Musc Foundation For Research Development | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders |
| US20140275178A1 (en) * | 2013-03-13 | 2014-09-18 | Musc Foundation For Research Development | Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders |
| US8921401B2 (en) | 2013-02-07 | 2014-12-30 | Musc Foundation For Research Development | Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders |
| DK2956056T3 (da) | 2013-03-14 | 2019-09-16 | Univ Laval | Elektroretinografisystem (erg) til vurdering af psykiatriske lidelser |
| CA2957785C (en) | 2014-08-11 | 2023-01-03 | Angion Biomedica Corporation | Cytochrome p450 inhibitors and uses thereof |
| CA2970819A1 (en) | 2014-12-31 | 2016-07-07 | Angion Biomedica Corp. | Methods and agents for treating disease |
| CN104803946A (zh) * | 2015-03-03 | 2015-07-29 | 佛山市赛维斯医药科技有限公司 | 含腈基噻唑和环戊二烯结构的ptp1b抑制剂及其用途 |
| WO2016176420A1 (en) * | 2015-04-30 | 2016-11-03 | Musc Foundation For Research Development | Oxindole compounds and pharmaceutical compositions thereof |
| HUE057041T2 (hu) | 2015-07-06 | 2022-04-28 | Alkermes Inc | Hiszton deacetiláz hetero-halogén gátlói |
| WO2017007755A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| TWI666023B (zh) * | 2016-09-26 | 2019-07-21 | 台灣粒線體應用技術股份有限公司 | 餘甘子萃取物用於製備保護視網膜中粒線體的醫藥組合物的用途 |
| US10967019B2 (en) | 2015-11-30 | 2021-04-06 | Taiwan Mitochondrion Applied Technology Co., Ltd. | Method for protecting mitochondria in retina cell |
| EP3426653B1 (en) * | 2016-03-11 | 2021-12-15 | AC Immune SA | Bicyclic compounds for diagnosis and therapy |
| HRP20220223T1 (hr) | 2017-01-11 | 2022-04-29 | Alkermes, Inc. | Biciklički inhibitori histon deacetilaze |
| US11225475B2 (en) | 2017-08-07 | 2022-01-18 | Alkermes, Inc. | Substituted pyridines as inhibitors of histone deacetylase |
| MX2021012250A (es) | 2019-04-11 | 2022-01-18 | Angion Biomedica Corp | Formas solidas de (e)-3-[2-(2-tienil)vinil]-1h-pirazol. |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| KR20250133471A (ko) | 2020-02-18 | 2025-09-05 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| BR112022019113A2 (pt) | 2020-03-26 | 2022-12-06 | Diamentis Inc | Sistemas e métodos para processar dados de sinal da retina e identificar condições |
| AU2022256476B2 (en) | 2021-04-16 | 2025-06-05 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| CA3228162A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| KR20240138099A (ko) * | 2022-01-26 | 2024-09-20 | 쑤저우 젠하우스 바이오 컴퍼니 리미티드 | Mtap 결실 암을 치료하기 위한 메티오닌 아데노실트랜스퍼라제 2a 억제제 |
| WO2023150878A1 (en) | 2022-02-09 | 2023-08-17 | Diamentis Inc. | Systems and methods for retinal stimulation and/or collecting retinal signal data |
| EP4582423A1 (en) * | 2022-10-13 | 2025-07-09 | Hanmi Pharm. Co., Ltd. | Novel tricyclic derivative compound and uses thereof |
| AR131380A1 (es) | 2022-12-16 | 2025-03-12 | Astrazeneca Ab | Purinas 2,6,9-trisustituidas |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA962269A (en) * | 1971-05-05 | 1975-02-04 | Uniroyal Ltd. | Thiazoles, and their use as insecticides |
| US3852293A (en) * | 1972-06-21 | 1974-12-03 | Uniroyal Inc | 4-phenyl-2-(3-pyridyl)-thiazole carboxamides |
| JPS57183768A (en) * | 1981-05-06 | 1982-11-12 | Kanto Ishi Pharma Co Ltd | 4-methyl-5-(o-carboxyphenyl)carbamoylthiazole derivative and its preparation |
| US4788207A (en) * | 1988-02-29 | 1988-11-29 | Fmc Corporation | Photoactivated miticidal and insecticidal ethynylthiazoles |
| DE19845402B4 (de) * | 1998-10-02 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| EP1402900A1 (en) * | 2001-06-11 | 2004-03-31 | Takeda Chemical Industries, Ltd. | Medicinal compositions |
| US7259175B2 (en) * | 2002-02-25 | 2007-08-21 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| PT1511710E (pt) * | 2002-05-31 | 2014-02-26 | Proteotech Inc | Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson |
| CA2599992A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Acridine and quinoline dervatives as sirtuin modulators |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| GB0701426D0 (en) * | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
| TW200916472A (en) * | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| RU2007139634A (ru) * | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
| WO2009064388A2 (en) * | 2007-11-09 | 2009-05-22 | Liu Jun O | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders |
-
2011
- 2011-03-24 US US13/636,754 patent/US20130137728A1/en not_active Abandoned
- 2011-03-24 CA CA2794018A patent/CA2794018C/en not_active Expired - Fee Related
- 2011-03-24 JP JP2013501494A patent/JP2013522376A/ja active Pending
- 2011-03-24 AU AU2011232347A patent/AU2011232347B2/en not_active Ceased
- 2011-03-24 EP EP11715106A patent/EP2550260A1/en not_active Withdrawn
- 2011-03-24 WO PCT/US2011/029846 patent/WO2011119869A1/en not_active Ceased
-
2015
- 2015-09-28 JP JP2015189524A patent/JP2015232051A/ja active Pending
-
2016
- 2016-01-15 US US14/996,662 patent/US20160237074A1/en not_active Abandoned
- 2016-08-09 JP JP2016156126A patent/JP2016188257A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7057317B2 (ja) | 疾患の治療のための二重機構阻害剤 | |
| EP2326623B1 (en) | Beta-and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | |
| JP5042215B2 (ja) | 網膜疾患を処置するための組成物および方法 | |
| CN102264693B (zh) | 用作线粒体通透性转变抑制剂的丙烯酰胺衍生物 | |
| TWI376370B (en) | Compounds for inflammation and immune-related uses | |
| TW495498B (en) | Amide derivative and a pharmaceutical composition containing the same as a Ca2+ release activated Ca2+ channel inhibitor | |
| ES2661394T3 (es) | Derivados de di- y tri-heteroarilo como inhibidores de la agregación de proteínas | |
| CN102030700B (zh) | 苯甲酰胺基羧酸类化合物及其制法和药物用途 | |
| WO2017184604A1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| CA2855759C (en) | Tricyclic compounds, compositions comprising them and uses thereof | |
| KR102307037B1 (ko) | 심폐 장애들의 치료를 위한 스핑고신-1-포스페이트 수용체 조절제들 | |
| KR102430906B1 (ko) | Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법 | |
| KR20140048239A (ko) | 아미노 프로판디올 유도체, 제조방법 및 약제학적 조성물 및 사용 | |
| CA3133825A1 (en) | Compounds and compositions as modulators of tlr signaling | |
| JP2014523887A5 (enExample) | ||
| WO2013078237A1 (en) | N-arylylmethylindazole modulators of pparg | |
| WO2014175832A1 (en) | Wnt pathway modulators | |
| JP7208649B2 (ja) | Ａｌｃａｔ１の阻害剤として有用な化合物 | |
| JP2021515787A (ja) | アミノ−ベンゾイソチアゾール及びアミノ−ベンゾイソチアジアゾールのアミド化合物 | |
| CN102807557A (zh) | 3h-1,2-二硫环戊烯-3-硫酮类化合物及其应用 | |
| MXPA06014797A (es) | Procesos para preparacion de antagonistas de receptor de hormona que libera gonadotropina. | |
| KR20230118602A (ko) | Enpp1 및 cdnp의 억제제로서의 포스포네이트 | |
| EP4650002A1 (en) | Aniline-based modulators of the nuclear receptor tlx (nr2e1) | |
| CN115504902A (zh) | 5-氯水杨酰胺类衍生物、其制备方法及其作为药物的用途 | |
| CA3191714A1 (en) | Benzylamine derivative, preparation method therefor and use thereof |